Long-term prognosis of vaccine-induced contact allergy to aluminium: Third patch-test with additional test preparations.

aluminium aluminium adsorbed vaccines aluminium allergy childhood vaccination contact allergy immunology patch test side effects tolerance

Journal

Contact dermatitis
ISSN: 1600-0536
Titre abrégé: Contact Dermatitis
Pays: England
ID NLM: 7604950

Informations de publication

Date de publication:
Nov 2023
Historique:
revised: 04 07 2023
received: 11 05 2023
accepted: 14 07 2023
medline: 5 10 2023
pubmed: 7 8 2023
entrez: 7 8 2023
Statut: ppublish

Résumé

A high incidence of local itching subcutaneous nodules and aluminium allergy was observed in clinical trials of a new aluminium adsorbed pertussis vaccine in Gothenburg, Sweden, in the 1990s. A total of 495 children with itching nodules were patch tested with aluminium chloride hexahydrate 2% and an empty Finn Chamber®, 377 (76%) with positive reactions. When 241 of them were re-tested some years later 186 (3 out of 4) had unexpectedly lost their patch test reactivity. To investigate the long-term prognosis of vaccine-induced contact allergy to aluminium by a third patch test about 20 years after Patch test I. Twenty individuals with positive and 11 with negative results in Patch test II were tested a third time with the same sensitisers as in in the first two tests. Three additional aluminium preparations were also tested. A total 15 out of 20 persons with positive results in the second test had lost their patch test reactivity. Two of 11 with negative tests had turned positive again. The addition of the preparations gave no conclusive results. Contact allergy to aluminium caused by vaccination with aluminium-adsorbed vaccines in childhood seems to fade away with time as measured by loss of patch test reactivity.

Sections du résumé

BACKGROUND BACKGROUND
A high incidence of local itching subcutaneous nodules and aluminium allergy was observed in clinical trials of a new aluminium adsorbed pertussis vaccine in Gothenburg, Sweden, in the 1990s. A total of 495 children with itching nodules were patch tested with aluminium chloride hexahydrate 2% and an empty Finn Chamber®, 377 (76%) with positive reactions. When 241 of them were re-tested some years later 186 (3 out of 4) had unexpectedly lost their patch test reactivity.
AIM OBJECTIVE
To investigate the long-term prognosis of vaccine-induced contact allergy to aluminium by a third patch test about 20 years after Patch test I.
METHODS METHODS
Twenty individuals with positive and 11 with negative results in Patch test II were tested a third time with the same sensitisers as in in the first two tests. Three additional aluminium preparations were also tested.
RESULTS RESULTS
A total 15 out of 20 persons with positive results in the second test had lost their patch test reactivity. Two of 11 with negative tests had turned positive again. The addition of the preparations gave no conclusive results.
CONCLUSION CONCLUSIONS
Contact allergy to aluminium caused by vaccination with aluminium-adsorbed vaccines in childhood seems to fade away with time as measured by loss of patch test reactivity.

Identifiants

pubmed: 37548037
doi: 10.1111/cod.14386
doi:

Substances chimiques

Aluminum CPD4NFA903
Pertussis Vaccine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

359-367

Subventions

Organisme : ALF-Agreement
ID : ALFGBG-814381
Organisme : ALF-Agreement
ID : ALFGBG-932683
Organisme : ALF-Agreement
ID : ALFGBG-938116

Informations de copyright

© 2023 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd.

Références

Bergfors E, Trollfors B, Inerot A. Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer. Vaccine. 2003;22(1):64-69.
Gente Lidholm A, Bergfors E, Inerot A, Blomgren U, Gillstedt M, Trollfors B. Unexpected loss of contact allergy to aluminium induced by vaccine. Contact Dermatitis. 2013;68(5):286-292. doi:10.1111/cod.12053
Lidholm AG, Inerot A, Gillstedt M, Bergfors E, Trollfors B. Long-term clinical course and prognosis of vaccine-related persistent itching nodules (1997-2019): an observational study. Vaccine X. 2022;11:100163. doi:10.1016/j.jvacx.2022.100163
Bergfors E, Bjorkelund C, Trollfors B. Nineteen cases of persistent pruritic nodules and contact allergy to aluminium after injection of commonly used aluminium-adsorbed vaccines. Eur J Pediatr. 2005;164(11):691-697. doi:10.1007/s00431-005-1704-1
Kaaber K, Nielsen AO, Veien NK. Vaccination granulomas and aluminium allergy: course and prognostic factors. Contact Dermatitis. 1992;26(5):304-306.
Veien NK, Hattel T, Justesen O, Norholm A. Aluminium allergy. Contact Dermatitis. 1986;15(5):295-297.
Bergfors E, Trollfors B, Inerot A, Gente LA. Contact allergy to aluminium induced by commonly used pediatric vaccines. Clin Transl Med. 2017;6(1):4. doi:10.1186/s40169-016-0129-y
Ozden MG, Kefeli M, Aydin F, Senturk N, Canturk T, Turanli AY. Persistent subcutaneous nodules after immunotherapy injections for allergic asthma. J Cutan Pathol. 2009;36(7):812-814. doi:10.1111/j.1600-0560.2008.01152.x
Johansen JD, Aalto-Korte K, Agner T, et al. European society of contact dermatitis guideline for diagnostic patch testing-recommendations on best practice. Contact Dermatitis. 2015;73(4):195-221. doi:10.1111/cod.12432
Lee EE, Maibach HI. Is contact allergy in man lifelong? An overview of patch test follow-ups. Contact Dermatitis. 2001;44(3):137-139.
Dittmar D, Ofenloch RF, Schuttelaar MLA. Persistence of contact allergy: a retrospective analysis. Contact Dermatitis. 2018;78(2):143-150. doi:10.1111/cod.12912
Ekqvist S, Svedman C, Lundh T, Möller H, Björk J, Bruze M. A correlation found between gold concentration in blood and patch test reactions in patients with coronary stents. Contact Dermatitis. 2008;59(3):137-142. doi:10.1111/j.1600-0536.2008.01401.x
Ekqvist S, Lundh T, Svedman C, et al. Does gold concentration in the blood influence the result of patch testing to gold? Br J Dermatol. 2009;160(5):1016-1021. doi:10.1111/j.1365-2133.2009.09065.x
Siemund I, Mowitz M, Zimerson E, Bruze M, Hindsen M. Variation in aluminium patch test reactivity over time. Contact Dermatitis. 2017;77(5):288-296. doi:10.1111/cod.12836
Masjedi K, Bruze M, Hindsén M, Minang J, Ahlborg N. Is the variability of nickel patch test reactivity over time associated with fluctuations in the systemic t-cell reactivity to nickel? Br J Dermatol. 2009;161(1):102-109. doi:10.1111/j.1365-2133.2009.09182.x
Bruze M, Frick-Engfeldt M, Gruvberger B, Isaksson M. Variation in the amount of petrolatum preparation applied at patch testing. Contact Dermatitis. 2007;56(1):38-42. doi:10.1111/j.1600-0536.2007.00985.x
Bruze M, Lundh K, Gruvberger B, Hindsen M. Aluminium chloride hexahydrate at 2% is insufficient to trace contact allergy to aluminium. Contact Dermatitis. 2008;59(3):183-184. doi:10.1111/j.1600-0536.2008.01394.x
Bergfors E, Inerot A, Falk L, Nyström U, Trollfors B. Patch testing children with aluminium chloride hexahydrate in petrolatum: a review and a recommendation. Contact Dermatitis. 2019;81(2):81-88. doi:10.1111/cod.13303
Salik E, Lovik I, Andersen KE, Bygum A. Persistent skin reactions and aluminium hypersensitivity induced by childhood vaccines. Acta Derm Venereol. 2016;96(7):967-971. doi:10.2340/00015555-2432
Goiset A, Darrigade AS, Labreze C, Boralevi F, Milpied B. Aluminium sensitization in a French paediatric patch test population. Contact Dermatitis. 2018;79(6):382-383. doi:10.1111/cod.13087
Gente Lidholm A, Inerot A, Gillstedt M, Bergfors E, Trollfors B. Comparison of reactivity to a metallic disc and 2% aluminium salt in 366 children, and reproducibility over time for 241 young adults with childhood vaccine-related aluminium contact allergy. Contact Dermatitis. 2018;79:26-30. doi:10.1111/cod.12977
Bergfors E, Trollfors B. Sixty-four children with persistent itching nodules and contact allergy to aluminium after vaccination with aluminium-adsorbed vaccines-prognosis and outcome after booster vaccination. Eur J Pediatr. 2013;172(2):171-177. doi:10.1007/s00431-012-1841-2

Auteurs

Anette Gente Lidholm (AG)

Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Dermatology and Venereology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.

Annica Inerot (A)

Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Dermatology and Venereology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.

Martin Gillstedt (M)

Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Dermatology and Venereology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.

Elisabet Bergfors (E)

General Practice/Family Medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Birger Trollfors (B)

Department of Paediatrics, Sahlgrenska University Hospital, Gothenburg, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH